|
|
|
 |
 |
|
|
|
DESCRIPTION
According to the National Academy of Clinical Biochemistry guidelines for the use of cardiac markers in coronary artery disease, troponin I is definitive of acute myocardial infraction. The new Access AccutnI assay was designed for rapid turnaround and improved sensitivity and specificity, helping laboratories meet a new standard of care in the management of patients with cardiac disease.
Features Speed and Ease-of-Use Improve Efficiency Time to result of 12 minutes allows laboratories to deliver results in less than 30 minutes from sample draw. The assay uses the preferred sample type, heparinized plasma, for rapid sample processing. Stable, liquid calibrators and controls improve ease of use. A curve stability of 56 days reduces both time required for calibration and the costs associated with calibration, while providing the technical benefits of multi-point calibration. Reliable Results for Greater Confidence Antibodies specific to the stable region of the cTnI molecule improve sample integrity and increase reliability of results. Minimal response to heterophile interferences increases confidence in results, reducing delays associated with repeat analysis. Excellent clinical sensitivity and specificity reduces laboratory consultation with physicians. Ordering Information Access Troponin I Control QC
DOWNLOADS
BECKMAN COULTER website
Prices are quoted in euro (taxes excluded) and apply in the Benelux (recycling fee included). They are subject to change without notice. We reserve the right to adjust pricing errors and to limit quantities.
|
|
|
